Congress Will Reauthorize Drug Review Fee Program
Pharmaceutical manufacturers and biotech firms will face a new regulatory fee framework through 2032.
Updated on Sept. 21, 2026 in Healthcare
Live Poll
Should the federal government continue funding FDA medication reviews through manufacturer fees?
Congress is preparing to reauthorize the Prescription Drug User Fee Act before the current program expires on September 30, 2027. The legislation establishes the funding mechanism for FDA medication reviews, a process that has influenced the regulatory landscape since 1992.
Why it matters
This program provides the financial foundation for FDA drug reviews, directly impacting the speed and compliance requirements for market entry. As negotiations for the PDUFA VIII framework proceed, companies must prepare for changes in the fee structures that sustain the agency's review processes.
The PDUFA program facilitates a system where drug makers fund FDA operations, with the U.S. currently serving as the first approval market for 70% of new medicines. In 2017, industry activity included 1,735 clinical trials in Florida alone, which saw 93,375 participants.
The players
FDA
The federal agency responsible for regulating food and drug safety through clinical trial oversight and market approval.
Secretary of Health and Human Services
The federal official tasked with submitting the final reauthorization legislative package to Congress.
The details
The reauthorization process involves the Secretary of Health and Human Services delivering a final legislative package to Congress by January 15, 2027. This framework dictates how manufacturers pay fees to the FDA to expedite the review of new medication applications. The current cycle builds upon planning that began with a kickoff meeting in July 2025 and a public input session held on September 16, 2026.
Timeline
1992: The Prescription Drug User Fee Act was initially enacted.
2017: Baseline data year for Florida research investments and clinical trial participation.
July 2025: First preparatory meeting for the PDUFA VIII framework.
September 16, 2026: Public meeting held to gather input on legislative requirements.
September 30, 2027: Current PDUFA program authorization expires.
Market Landscape
The upcoming reauthorization of the Prescription Drug User Fee Act maintains the established funding structure that has governed drug approvals since 1992. This cycle follows the pattern of previous multi-year renewals that harmonize industry financial contributions with agency review performance goals.
Operators in the pharmaceutical and biotech sectors should monitor the upcoming fee structure adjustments that will take effect for the 2027-2032 cycle. Review your long-term research and development budgets to account for potential changes in user fee obligations.
The takeaway
The PDUFA VIII negotiations represent a critical window for companies to anticipate regulatory overhead costs for the next five years. Monitor the January 2027 legislative delivery for specific fee schedules that will dictate the cost of bringing new drugs to market through 2032.
What happens next
The Secretary of Health and Human Services is scheduled to deliver the final legislative package to Congress on January 15, 2027.
Further reading
For broader context on federal regulatory shifts, explore the Healthcare section.
Live Poll
Should the federal government continue funding FDA medication reviews through manufacturer fees?
